# Phase 3 Study of Tadalafil Once-Daily in Asian Men With Benign Prostatic Hyperplasia (BPH)

> **NCT01460342** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 610 (actual)

## Conditions studied

- Benign Prostatic Hyperplasia

## Interventions

- **DRUG:** Tadalafil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01460342
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 610 (ACTUAL)
- **Last updated:** 2013-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01460342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01460342, "Phase 3 Study of Tadalafil Once-Daily in Asian Men With Benign Prostatic Hyperplasia (BPH)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01460342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*